The Patent Finder

Akeso Biopharma, Inc.

Also on record
Records under this name other than the patents Akeso Biopharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 17 patents it holds.

Back to Akeso Biopharma, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
17/272,121Methods for Treating a Tumor Using an ANTI-VEGFA/PD-1 Bifunctional Antibody
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
17/419,109Antibody Against Human IL-4RA and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
17/630,467ANTI-CTLA4-ANTI-PD-1 Bispecific Antibody and Uses Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
17/630,477ANTI-PD-1 Antibody and Medical Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
17/779,425ANTI-PD-1-ANTI-VEGFA Bispecific Antibody, Pharmaceutical Composition and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/021,167ANTI-CD73 Antibody and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/024,471ANTI-CD47 Monoclonal Antibody and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/024,478Pharmaceutical Combination Containing ANTI-PD-1-ANTI-VEGFA Bispecific Antibody, and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/250,010ANTI-CD73 Antibody and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/264,138Pharmaceutical Composition Comprising Anti-Tigit Antibody and ANTI-PD-1/ANTI-VEGFA Bispecific Antibody, and Use Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
10 of 29 records shown.
Pro members see all 29.
Pro members: see all 29 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited